Summary of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Keywords: آنژیوتانسین تبدیل آنزیم (ACE); CVD; cardiovascular disease; HER2; human epidermal growth factor receptor 2; HF; heart failure; T-DM1; trastuzumab, pertuzumab, trastuzumab-emtansine; TKI; lapatinib; LV; left ventricular; ACE; angiotensin-converting enzyme (ACE) inhibitors; VEGF; vascula